Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients

Neuropsychobiology

Volumn 36, Issue 1, 1997, Pages 32-36

  Jann, Michael W ^a   Crabtree, Brian L ^b   Pitts, Wesley M ^b   Lam, Francis ^c   Carter, Gary ^a,d  

^a MERCER UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d Georgia Mental Health Institute   (United States)

Author keywords

Brief psychiatric rating scale; Haloperidol; Plasma alpha one acid glycoprotein; Schizophrenia

Indexed keywords

HALOPERIDOL; OROSOMUCOID; REDUCED HALOPERIDOL;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISPOSITION; DYSKINESIA; ELECTROCHEMICAL DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNODIFFUSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; OROSOMUCOID; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0030957754     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000119357     Document Type: Article

References (24)

1. Kroner JMH, Wilting J, Janssen LHM: Drug binding to human alpha-one acid glycoprotein in health and disease, Pharmacol Rev 1988:40: 1-47.
2. Kchoe WA, Kwentus JA, Sheffel WB, Harral-son AF: Increased alpha-one acid glycoprotein in depression lower free fraction of imipra-mine, Biol Psychiatry 1991;29:489-493.
3. Nemeroff CM, Krishman RR, Blazer DG, Knight DL, Benjamin D, Meyerson LR: Elevated plasma concentrations of alpha-one acid glycoprotein, a putative endogenous inhibitor of the titrated imipramine binding site in depressed patients, Arch Gen Psychiatry 1990; 47:337-340.
4. Bock E, Weeke B, Rafaelsen OJ: Serum proteins in acutely psychotic patients, J Psychiatr Res 1971:9:19.
5. Miyoshi T, Sukimoto K, Otsgiri M: Investigation of the interaction mode of phenothiazine neuroleptics with alpha-one acid glycoprotein, J Pharm Pharmacol 1992;44:28-33.
6. Piafsky KM, Borga O: Plasma protein binding of basic drugs, Clin Pharmacol Ther 1978:22: 545-549.
7. Schley J, Muller-Oerlinghausen B: Investigation of the binding of various tricyclic neuroleptics and antidepressants to alpha-one acid glycoprotein, J Pharm Pharmacol 1986;38: 102-106.
8. Kombuth ML, Hutchins LG, Eichelman BS: Binding of psychotropic drugs to isolated alpha-one aeid glycoprotein, Biochcm Pharmacol 1981:30:2435-2441.
9. Schley J, Muller-Oerlinghausen B: The binding of chemically different psychotropic drugs to alpha-one acid glycoprotein, Pharmacopsychiatry 1983;16:82-85.
10. Levinson I, Levine S: Negative correlation between alpha-one acid glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia, Biol Psychiatry 1995; 38:198-200.
11. Forsman A, Ohman R: Studies on serum protein binding of haloperidol, Curr Ther Res 1977:21:245-255.
12. Freedberg KA, Innis RB, Creese I, Snyder SH: Antischizophrenic drugs: Differential plasma protein binding and therapeutic activity, Life Sei 1979;24:2467-2474.
13. Jann MW, Um YWF, Chang WH: Reversible metabolism of drugs, Drug Metab Drug Interact 1994:11:1-25.
14. Caccia S, Garattini S: Formation of active metabolites of psychotropic drugs, Clin Pharma-cokinet 1990:18:434-459.
15. Eyles DW, Stedman TJ, Pond SM: Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: Evaluation of possible mechanisms, Psychopharmacology 1994; 116:161-166.
16. Jann MW, Chang WH, Davis CM, Chen TY, Deng HC, Lung FW, Ereshefsky L, Saklad SR, Richards AL: Haloperidol and reduced haloperidol plasma levels in Chinese versus non-Chinese patients, Psychiatry Res 1989:30:45-52.
17. Conly R, An Nguyen A, Tamminga C: Haloperidol kinetics and clinical response, Schi-zophr Res 1991:4:287.
18. Chang WH: Reduced haloperidol: A factor in determining the therapeutic benefit of haloperidol treatment? Psychopharmacology 1992: 106:289-296.
19. Froemming JH, Lam YWF, Jann MW, Davis CM: Pharmacokinetics of haloperidol, Clin Pharmacokinet 1989:17:392-421.
20. Eddington ND, Young DL: Sensitive electrochemical high-performance liquid chromatography assay for the simultaneous determination of haloperidol and reduced haloperidol, J Pharm Sei 1988:77:541-543.
21. Mancini G, Carbonara AO, Hcremans JF: Immunochemical quantitation of antigens by single radial immunodiffusion, Immunochemis-try 1965;2:235-254.
22. Guy W: ECDEU Assessment Manual for Psychopharmacology. 1976.
23. Van Putten T, Marder SR, Mintz J, Poland R: Haloperidol plasma levels and clinical response: A therapeutic window relationship, Am J Psychiatry 1992:149:500-505.
24. DeVane CL, Lim C, Carson SW, Tingle D, Hackett L, Ware MR: Effect of electroconvul-sive therapy on serum concentration of alpha-one acid glycoprotein, Biol Psychiatry 1991:30: 116-120.